NASDAQ:CPRX
Catalyst Pharmaceuticals Stock News
$15.06
-0.270 (-1.76%)
At Close: Jun 14, 2024
3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)
02:29pm, Thursday, 16'th Mar 2023
Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse
01:46pm, Thursday, 16'th Mar 2023
Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.
Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates
07:05pm, Wednesday, 15'th Mar 2023
Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
04:22pm, Wednesday, 15'th Mar 2023
Catalyst Pharmaceuticals topped fourth-quarter expectations and delivered strong guidance. In response, CPRX stock rose late Wednesday.
Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know
10:44am, Friday, 10'th Mar 2023
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
08:03am, Wednesday, 01'st Mar 2023
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET
3 Top Profitable Stocks to Buy on Solid Net Income Ratio
09:02am, Tuesday, 28'th Feb 2023
Lamb Weston (LW), Catalyst Pharmaceuticals (CPRX) and Northeast Community Bancorp (NECB) are some of the top picks with a high net income ratio.
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Monday, 27'th Feb 2023
Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Monday, 27'th Feb 2023
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
02:18pm, Friday, 24'th Feb 2023
Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
02:06pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
01:03pm, Wednesday, 22'nd Feb 2023 GlobeNewswire Inc.
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023
Catalyst Pharmaceutical (CPRX) Stock Moves -1.74%: What You Should Know
10:50pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.25, moving -1.74% from the previous trading session.
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?
05:15pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treat
Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic?
02:30pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Based on the average brokerage recommendation (ABR), Catalyst (CPRX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this
